Clustering according to urolithin metabotype explains the interindividual variability in the improvement of cardiovascular risk biomarkers in overweight-obese individuals consuming pomegranate: A randomized clinical trial

Molecular Nutrition and Food Research

Volumn 61, Issue 5, 2017, Pages

  González Sarrías, Antonio ^a   García Villalba, Rocío ^a   Romo Vaquero, María ^a   Alasalvar, Cesarettin ^b   Örem, Asim ^c   Zafrilla, Pilar ^d   Tomás Barberán, Francisco A ^a   Selma, María V ^a   Espín, Juan Carlos ^a  

^a RESEARCH GROUP ON QUALITY   (Spain)

^b MATERIALS INSTITUTE   (Turkey)

^c KARADENIZ TECHNICAL UNIVERSITY   (Turkey)

^d CATHOLIC UNIVERSITY OF MURCIA   (Spain)

Author keywords

Cardiometabolic; EFSA; Gut microbiota; Metabotype; Urolithins

Indexed keywords

BIOLOGICAL MARKER; CHOLESTEROL; COUMARIN DERIVATIVE; PLANT EXTRACT; POLYPHENOL; TANNIN;

ADULT; AGED; BLOOD; CARDIOVASCULAR DISEASE; CHEMISTRY; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; FEMALE; GASTROINTESTINAL TRACT; HUMAN; INTESTINE FLORA; LYTHRACEAE; MALE; METABOLISM; MIDDLE AGED; OBESITY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR;

ADULT; AGED; BIOMARKERS; CARDIOVASCULAR DISEASES; CHOLESTEROL; COUMARINS; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; GASTROINTESTINAL MICROBIOME; GASTROINTESTINAL TRACT; HUMANS; HYDROLYZABLE TANNINS; MALE; MIDDLE AGED; OBESITY; OVERWEIGHT; PLANT EXTRACTS; POLYPHENOLS; PUNICACEAE; RISK FACTORS;

EID: 85018992803     PISSN: 16134125     EISSN: 16134133     Source Type: Journal    
DOI: 10.1002/mnfr.201600830     Document Type: Article

References (53)

1. Kim, S. H., Després, J. P., Koh, K. K., Obesity and cardiovascular disease: friend or foe? Eur. Heart J. 2015, doi:10.1093/eurheartj/ehv509.
2. Piepoli, M. F., Hoes, A. W., Agewall, S., Albus, C. et al., 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur. Heart J. 2016, 37, 2315–2381.
3. Roberts, L. D., Gerszten, R. E., Toward new biomarkers of cardiometabolic diseases. Cell Metab. 2013, 18, 43–50.
4. Boekholdt, S. M., Hovingh, G. K., Mora, S., Arsenault, B. J. et al., Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials. J. Am. Coll. Cardiol. 2014, 64, 485–494.
5. Jain, K. K., Personalized medicine. Curr. Opin. Mol. Ther. 2002, 4, 548–558.
6. Frankenfeld, C. L., Atkinson, C., Thomas, W. K., Gonzalez, A. et al., High concordance of daidzein-metabolizing phenotypes in individuals measured 1 to 3 years apart. Br. J. Nutr. 2005, 94, 873–876.
7. Frankenfeld, C. L., Atkinson, C., Wähälä, K., Lampe, J. W., Obesity prevalence in relation to gut microbial environments capable of producing equol or O-desmethylangolensin from the isoflavone daidzein. Eur. J. Clin. Nutr. 2014, 68, 526–530.
8. Vlachojannis, C., Erne, P., Schoenenberger, A. W., Chrubasik-Hausmann, S., A critical evaluation of the clinical evidence for pomegranate preparations in the prevention and treatment of cardiovascular diseases. Phytother. Res. 2015, 29, 501–508.
9. Mosele, J. I., Gosalbes, M. J., Macià, A., Rubió, L. et al., Effect of daily intake of pomegranate juice on fecal microbiota and feces metabolites from healthy volunteers. Mol. Nutr. Food Res. 2015, 59, 1942–1953.
10. Banihani, S. A., Makahleh, S. M., El-Akawi, Z., Al-Fashtaki, R. A. et al., Fresh pomegranate juice ameliorates insulin resistance, enhances β-cell function, and decreases fasting serum glucose in type 2 diabetic patients. Nutr. Res. 2014, 34, 862–867.
11. Shishehbor, F., Mohammad Shahi, M., Zarei, M., Saki, A. et al., Effects of concentrated pomegranate juice on subclinical inflammation and cardiometabolic risk factors for type 2 diabetes: a quasi-experimental study. Int. J. Endocrinol. Metab. 2016, 14:e33835.
12. Kojadinovic, M. I., Arsic, A. C., Debeljak-Martacic, J. D., Konic-Ristic, A. I. et al., Pomegranate juice consumption decrease blood lipid peroxidation and level of arachidonic acid in women with metabolic syndrome. J. Sci. Food Agric. 2016, doi: 10.1002/jsfa.7977.
13. Sahebkar, A., Simental-Mendía, L. E., Giorgini, P., Ferri, C. et al., Lipid profile changes after pomegranate consumption: a systematic review and meta-analysis of randomized controlled trials. Phytomedicine 2016, 23, 1103–1112.
14. Bolca, S., Van de Wiele, T., Possemiers, S., Gut metabotypes govern health effects of dietary polyphenols. Curr. Opin. Biotechnol. 2013, 24, 220–225.
15. Tomás-Barberán, F. A., García-Villalba, R., González-Sarrías, A., Selma, M. V. et al., Ellagic acid metabolism by human gut microbiota: consistent observation of three urolithin phenotypes in intervention trials, independent of food source, age, and health status. J. Agric. Food Chem. 2014, 62, 6535–6538.
16. Manach, C., Milenkovic, D., Van de Wiele, T., Rodríguez-Mateos, A. et al., Addressing the inter-individual variation in response to consumption of plant food bioactives—towards a better understanding of their role in healthy ageing and cardiometabolic risk reduction. Mol. Nutr. Food Res. 2016, doi: 10.1002/mnfr.201600557.
17. Tomás-Barberán, F. A., González-Sarrías, A., García-Villalba, R., Núñez-Sánchez, M. A. et al., Urolithins, the rescue of 'old' metabolites to understand a 'new' concept: metabotypes as a nexus between phenolic metabolism, microbiota dysbiosis and host health status. Mol. Nutr. Food Res. 2016, doi: 10.1002/mnfr.201500901.
18. Selma, M. V., Romo-Vaquero, M., García-Villalba, R., González-Sarrías, A. et al., The human gut microbial ecology associated with overweight and obesity determines ellagic acid metabolism. Food Funct. 2016, 7, 1769–1774.
19. García-Villalba, R., Espín, J. C., Tomás-Barberán, F. A., Chromatographic and spectroscopic characterization of urolithins for their determination in biological samples after the intake of foods containing ellagitannins and ellagic acid. J. Chromatogr. A. 2016, 1428, 162–175.
20. García-Villalba, R., Espín, J. C., Aaby, K., Alasalvar, C. et al., Validated method for the characterization and quantification of extractable and nonextractable ellagitannins after acid hydrolysis in pomegranate fruits, juices, and extracts. J. Agric. Food Chem. 2015, 63,6555–6566.
21. De la Torre-Carbot, K., Chávez-Servín, J. L., Jaúregui, O., Castellote, A. I. et al., Elevated circulating LDL phenol levels in men who consumed virgin rather than refined olive oil are associated with less oxidation of plasma LDL. J. Nutr. 2010, 140, 501–508.
22. Nieman, D.C., Cialdella-Kam, L., Knab, A. M., Shanely, R. A., Influence of red pepper spice and turmeric on inflammation and oxidative stress biomarkers in overweight females: a metabolomics approach. Plant Foods Hum. Nutr. 2012, 67, 415–421.
23. Tomé-Carneiro, J., Gonzálvez, M., Larrosa, M., García-Almagro, F. J. et al., Consumption of a grape extract supplement containing resveratrol decreases oxidized LDL and ApoB in patients undergoing primary prevention of cardiovascular disease: a triple-blind, 6-month follow-up, placebo-controlled, randomized trial. Mol. Nutr. Food Res. 2012, 56, 810–821.
24. Sharma, S., Roberts, L. S., Hudes, M. L., Lustig, R. H. et al., Macronutrient intakes and cardio metabolic risk factors in high BMI African American children. Nutr. Metab. 2009, 6, 1–8.
25. Vega, G. L., Ma, P. T. S., Cater, N. B., Filipchuk, N. et al., Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome. Am. J. Cardiol. 2003, 91, 956–960.
26. Furet, J. P., Firmesse, O., Gourmelon, M., Bridonneau, C. et al., Comparative assessment of human and farm animal faecal microbiota using real-time quantitative PCR. FEMS Microbiol. Ecol. 2009, 68, 451–462.
27. Romo-Vaquero, M., García-Villalba, R., González-Sarrías, A., Beltrán, D., Interindividual variability in the human metabolism of ellagic acid: contribution of Gordonibacter to urolithin production. J. Funct. Foods 2015, 17, 785–791.
28. Schork, N. J., Personalized medicine: time for one-person trials. Nature 2015, 520, 609–611.
29. Pérez-Martínez, P., García-Rios, A., Delgado-Lista, J., Pérez-Jiménez, F. et al., Metabolic syndrome: evidences for a personalized nutrition. Mol. Nutr. Food Res. 2012, 56, 67–76.
30. García-Rios, A., Pérez-Martínez, P., Delgado-Lista, J., López-Miranda, J. et al., Nutrigenetics of the lipoprotein metabolism. Mol. Nutr. Food Res. 2012, 56, 171–183.
31. Milenkovic, D., Jude, B., Morand, C., miRNA as molecular target of polyphenols underlying their biological effects. Free Radic. Biol. Med. 2013, 64, 40–51.
32. Sonnenburg, J. L., Bäckhed, F., Diet-microbiota interactions as moderators of human metabolism. Nature. 2016, 535, 56–64.
33. Tomás-Barberán, F. A., Selma, M. V., Espín, J. C., Interactions of gut microbiota with dietary polyphenols and consequences to human health. Curr. Opin. Clin. Nutr. Metab. Care 2016, doi:10.1097/MCO.0000000000000314.
34. Kerimi, A., Williamson, G., At the interface of antioxidant signalling and cellular function: key polyphenol effects. Mol. Nutr. Food Res. 2016, 60, 1770–1788.
35. Tomé-Carneiro, J., Larrosa, M., González-Sarrías, A., Tomás-Barberán, F. A. et al., Resveratrol and clinical trials: the crossroad from in vitro studies to human evidence. Curr. Pharm. Des. 2013, 34, 6064–6093.
36. Núñez-Sánchez, M. A., González-Sarrías, A., Romo-Vaquero, M., García-Villalba, R. et al., Dietary phenolics against colorectal cancer—from promising preclinical results to poor translation into clinical trials: pitfalls and future needs. Mol. Nutr. Food Res. 2015, 59, 1274–1291.
37. Ye, Y. B., Chen, A. L., Lu, W., Zhuo, S. Y. et al., Daidzein and genistein fail to improve glycemic control and insulin sensitivity in Chinese women with impaired glucose regulation: a double-blind, randomized, placebo-controlled trial. Mol. Nutr. Food Res. 2015, 59, 240–249.
38. Rodríguez-Mateos, A., Cifuentes-Gómez, T., González-Salvador, I., Ottaviani, J. I. et al., Influence of age on the absorption, metabolism, and excretion of cocoa flavanols in healthy subjects. Mol. Nutr. Food Res. 2015, 59, 1504–1512.
39. Hazim, S., Curtis, P. J., Schär, M. Y., Ostertag, L. M. et al., Acute benefits of the microbial-derived isoflavone metabolite equol on arterial stiffness in men prospectively recruited according to equol producer phenotype: a double-blind randomized controlled trial. Am. J. Clin. Nutr. 2016, 103, 694–702.
40. Selma, M. V., Espín, J. C., Tomás-Barberán, F. A., Interaction between phenolics and gut microbiota: role in human health. J. Agric. Food Chem. 2009, 57, 6485–6501.
41. EFSA. Scientific Opinion on the substantiation of health claims related to pomegranate/pomegranate juice and maintenance of normal blood cholesterol concentrations (ID 1162, 1320, 2107, 2167), maintenance of normal erectile function (ID 1163), protection of lipids from oxidative damage (ID 1201, 1319, 2123), “antioxidant and anti-aging properties” (ID 1901), increase in appetite after unintentional weight loss leading to an increase in energy intake (ID 2122) and maintenance of normal blood glucose concentrations (ID 4471) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA J., 2010, 8, 1750 [22 pp.].
42. EFSA. Scientific opinion on the substantiation of a health claim related to a combination of pomegranate pomace extract and greater galangal rhizome powder and an increase in the number of motile spermatozoa in semen pursuant to Article 13(5) of Regulation (EC) No 1924/2006. EFSA J., 2015, 13, 4097 [16 pp.].
43. Emerging Risk Factors Collaboration, Wormser, D., Kaptoge, S., Di Angelantonio, E. et al., Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies. Lancet 2011, 377, 1085–1095.
44. Frankenfeld, C. L., Cardiometabolic risk and gut microbial phytoestrogen metabolite phenotypes. Mol. Nutr. Food Res 2016, doi: 10.1002/mnfr.201500900.
45. Reverri, E. J., Slupsky, C. M., Mishchuk, D. O., Steinberg, F. M., Metabolomics reveals differences between three daidzein metabolizing phenotypes in adults with cardiometabolic risk factors. Mol. Nutr. Food Res. 2016, doi: 10.1002/mnfr.201600132.
46. Cerdá, B., Tomás-Barberán, F. A., Espín, J. C., Metabolism of antioxidant and chemopreventive ellagitannins from strawberries, raspberries, walnuts, and oak-aged wine in humans: identification of biomarkers and individual variability. J. Agric. Food Chem. 2005, 53, 227–235.
47. Larrosa, M., González-Sarrías, A., Yáñez-Gascón, M. J., Selma, M. V. et al., Anti-inflammatory properties of a pomegranate extract and its metabolite urolithin-A in a colitis rat model and the effect of colon inflammation on phenolic metabolism. J. Nutr. Biochem. 2010, 21, 717–725.
48. Ishimoto, H., Shibata, M., Myojin, Y., Ito, H. et al., In vivo anti-inflammatory and antioxidant properties of ellagitannin metabolite urolithin A. Bioorg. Med. Chem. Lett. 2011, 21, 5901–5904.
49. Ryu, D., Mouchiroud, L., Andreux, P. A., Katsyuba, E. et al., Urolithin A induces mitophagy and prolongs lifespan in Celegans and increases muscle function in rodents. Nat. Med. 2016, 22, 879–888.
50. Nuñez-Sánchez, M.A., Dávalos, A., González-Sarrías, A., Casas-Agustench, P. et al., MicroRNAs expression in normal and malignant colon tissues as biomarkers of colorectal cancer and in response to pomegranate extracts consumption: critical issues to discern between modulatory effects and potential artefacts. Mol. Nutr. Food Res. 2015, 59, 1973—1986.
51. Bialonska, D., Ramnani, P., Kasimsetty, S. G., Muntha, K. R. et al., The influence of pomegranate by-product and punicalagins on selected groups of human intestinal microbiota. Int. J. Food Microbiol. 2010, 140, 175–182.
52. Li, Z., Henning, S. M., Lee, R. P., Lu, Q. Y. et al., Pomegranate extract induces ellagitannin metabolite formation and changes stool microbiota in healthy volunteers. Food Funct. 2015, 6, 2487–2495.
53. Sigurdardottir, V., Fagerberg, B., Hulthe, J., Circulating oxidized low-density lipoprotein (LDL) is associated with risk factors of the metabolic syndrome and LDL size in clinically healthy 58-year-old men (AIR study). J. Intern. Med. 2002, 252, 440–447.